RPTP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPTP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Raptor Pharmaceutical's depreciation, depletion and amortization for the three months ended in Jun. 2016 was $0.5 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Jun. 2016 was $1.9 Mil.
The historical data trend for Raptor Pharmaceutical's Depreciation, Depletion and Amortization can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raptor Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Aug09 | Aug10 | Aug11 | Aug12 | Dec13 | Dec14 | Dec15 | |||||||||||
Depreciation, Depletion and Amortization | Get a 7-Day Free Trial | 0.23 | 0.21 | 0.44 | 1.04 | 1.62 |
Raptor Pharmaceutical Quarterly Data | ||||||||||||||||||||
Aug11 | Nov11 | Feb12 | May12 | Aug12 | Nov12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | |
Depreciation, Depletion and Amortization | Get a 7-Day Free Trial | 0.39 | 0.40 | 0.47 | 0.51 | 0.52 |
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raptor Pharmaceutical (NAS:RPTP) Depreciation, Depletion and Amortization Explanation
One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.
For example:
If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).To create income statements that meet the matching principle, accountants use an expense called depreciation.
So, instead of reporting a $300 million purchase expense in 1982, the company might:
Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.To calculate depreciation, a company must make estimates and choices such as:
The cost of the assetThe range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.
Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.
A contra asset account is an account that offsets an asset account. So, for example a company might have:
Property, Plant, and Equipment - Gross: $150 millionIn this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.
It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.
This is a reminder that depreciation involves estimates and choices. It is not an infallible process.
Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of Raptor Pharmaceutical's Depreciation, Depletion and Amortization provided by GuruFocus.com. Please click on the following links to see related term pages.
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Krishna R Polu | officer: Chief Medical Officer | C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Michael P Smith | officer: Chief Financial Officer | 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Llew Keltner | director | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
David Happel | officer: Chief Commercial Officer | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Julie Smith | director, officer: President and CEO | C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Erich Sager | director | 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949 |
Georgia Erbez | officer: Chief Financial Officer | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Vijay B Samant | director | 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Patrice Rioux | other: CMO, Raptor Therapeutics | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.